GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Cyclically Adjusted PS Ratio

Alimera Sciences (Alimera Sciences) Cyclically Adjusted PS Ratio : 0.34 (As of May. 16, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Alimera Sciences's current share price is $3.28. Alimera Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $9.69. Alimera Sciences's Cyclically Adjusted PS Ratio for today is 0.34.

The historical rank and industry rank for Alimera Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

ALIM' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.15   Med: 0.79   Max: 4.11
Current: 0.34

During the past years, Alimera Sciences's highest Cyclically Adjusted PS Ratio was 4.11. The lowest was 0.15. And the median was 0.79.

ALIM's Cyclically Adjusted PS Ratio is ranked better than
90.5% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs ALIM: 0.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alimera Sciences's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.502. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $9.69 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alimera Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alimera Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Cyclically Adjusted PS Ratio Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 0.51 0.58 0.29 0.45

Alimera Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.23 0.30 0.32 0.45

Competitive Comparison of Alimera Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Cyclically Adjusted PS Ratio falls into.



Alimera Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alimera Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.28/9.69
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alimera Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alimera Sciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.502/129.4194*129.4194
=0.502

Current CPI (Dec. 2023) = 129.4194.

Alimera Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.872 99.695 1.132
201406 0.772 100.560 0.994
201409 0.879 100.428 1.133
201412 0.589 99.070 0.769
201503 1.332 99.621 1.730
201506 1.951 100.684 2.508
201509 2.330 100.392 3.004
201512 1.957 99.792 2.538
201603 1.934 100.470 2.491
201606 3.179 101.688 4.046
201609 2.219 101.861 2.819
201612 2.466 101.863 3.133
201703 1.531 102.862 1.926
201706 2.375 103.349 2.974
201709 2.145 104.136 2.666
201712 1.983 104.011 2.467
201803 2.067 105.290 2.541
201806 2.296 106.317 2.795
201809 2.368 106.507 2.877
201812 3.235 105.998 3.950
201903 2.733 107.251 3.298
201906 2.293 108.070 2.746
201909 2.715 108.329 3.244
201912 3.542 108.420 4.228
202003 2.918 108.902 3.468
202006 1.995 108.767 2.374
202009 2.461 109.815 2.900
202012 2.555 109.897 3.009
202103 1.949 111.754 2.257
202106 2.948 114.631 3.328
202109 1.755 115.734 1.963
202112 2.012 117.630 2.214
202203 1.702 121.301 1.816
202206 2.086 125.017 2.159
202209 1.943 125.227 2.008
202212 2.004 125.222 2.071
202303 1.926 127.348 1.957
202306 2.167 128.729 2.179
202309 0.728 129.860 0.726
202312 0.502 129.419 0.502

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alimera Sciences  (NAS:ALIM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alimera Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (Alimera Sciences) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Executives
Margaret Pax director 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko director C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont director 51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers other: Chairman Emeritus 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan director 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman 10 percent owner FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076